Advocacy - Government Coverage and Reimbursement Policies Take Action Federal Advocacy State Advocacy Local Advocacy Protect Access & Innovation: Infographics & Resources CLSAPAC CLSA Capitol Connection Become an Advocate Letters, Testimony and Comments December 30, 2013HR 3681 Accelerating Innovation in Medicine Act of 2013 April 16, 2013HR 1588 Medicare Drug Savings Act of 2013 April 16, 2013S 740 Medicare Drug Savings Act of 2013 January 23, 2013HR 351 Protecting Seniors’ Access to Medicare Act of 2013 April 8, 2019Multi-Stakeholder Letter to Administrator Verma: Opposing the CMS Regulation of Step Therapy in Part B Medicare Plans – April 2019 March 27, 2019Rep. Tom McClintock’s letter to Sec. Azar Expressing Concerns with Administration’s Proposed Part B Overhaul (Reference Pricing/International Pricing Index) – December 2018 March 13, 2019Bipartisan House Letter Opposing Trump Administration Proposal to Restrict Patient Access to HIV/AIDS Therapies in Medicare Part D (Rep. Barbara Lee) – March 2019 January 28, 2019145 Patient Groups Sign Partnership for Part D Access Letter to CMS Opposing Administration Restricted Access Proposal (Part D) – January 2019 January 25, 2019House Letter to Administration Opposing Changes to Protected Classes Policy in Medicare Part D – January 2019 December 31, 2018CLSA Comments to Administration on IPI Proposal ANPRM– December 2018 December 10, 2018CLSA Joins 338 Patient, Provider & Life Sciences Organizations to Express Concerns re Administration’s Proposed Part B Overhaul (Reference Pricing/International Pricing Index) – December 2018 September 12, 2018ASP Coalition Letter to Leadership: Opposing Prior Authorization and Step Therapy for Part B Drugs in Medicare Advantage – September 2018 August 1, 2018Multi-Stakeholder Letter on Value-Based Payment Models – August 2018 July 27, 2018CLSA Comments to Bipartisan Health Care Innovation Caucus – July 2018 July 16, 2018CLSA Comments to HHS Blueprint RFI – July 2018 July 16, 2018Part B Access for Seniors and Physicians (ASP) Coalition Letter to Sec. Azar on Blueprint RFI – July 2018 June 5, 2018CLSA Backgrounder on the Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5997) – June 2018 June 5, 2018CLSA Endorsement Letter – HR 5997 – The Ensuring Patient Access to Critical Breakthrough Products Act – June 2018 February 27, 2018State Association Endorsement Letter – The Ensuring Patient Access to Critical Breakthrough Products Act – February 2018 November 20, 2017CLSA Response to CMMI Request for Information: Innovation Center New Direction November 15, 2017Part B Access for Seniors and Physicians (ASP) Coalition Letter Urging CMS to Protect Patients Through CMMI – November 2017 November 2, 2017760+ Organizations Urge Repeal of the Independent Payment Advisory Board (IPAB)- November 2017 September 11, 2017CLSA Comments to CMS on Drug Coated Balloon Payment – September 2017 September 11, 2017CLSA Comments to CMS on Laboratory Date of Service Proposed Rule – September 2017 September 11, 2017CLSA Comments to CMS on Biosimilar Payments – September 2017 September 7, 2017Congressional Letter to Secretary Price on CMMI/Part B Drug Payment Model – September 2017 June 28, 2017Bipartisan Letter to Veterans Administration on Medical Device Late Payments – June 2017 June 8, 2017269 Health Care and Patient Advocacy Groups Ask Secretary Price to Oppose Harmful Cuts to Part B – June 2017 February 15, 2017CLSA Letter to Rep. Raul Ruiz in Support of Bill to Repeal the Independent Payment Advisory Board (H.R. 849) – February 2017 November 29, 2016600 Organizations Urge Repeal of the Independent Payment Advisory Board (IPAB)- November 2016 September 12, 2016CLSA Comments Regarding National Call for Proposed Improvements to ICER Value Assessment Framework – September 2016 July 20, 2016Patient Group Endorsement Letter – HR 5009 – The Ensuring Access to Critical Breakthrough Products Act – July 2016 July 6, 2016CLSA Endorsement Letter – HR 1427 – Medicare CGM Access Act – July 2016 June 20, 2016NIH/HHS Response to March-In Citizens Petition & Request for Public Hearing on Xtandi (enzalutamide) – June 2016 June 6, 2016State Association Endorsement Letter – HR 5009 – The Ensuring Access to Critical Breakthrough Products Act – June 2016 May 31, 2016CMS Response to Congressional Part B Letter Urging Withdrawal – May 2016 May 16, 2016Democratic Congressional Letter to CMS Expressing Concerns on Part B Rule – May 2016 May 13, 2016Congressional Letter to CMS Expressing Serious Concerns Over CMS Proposal – May 2016 May 9, 2016CLSA Comments to CMS Requesting Withdrawal of CMS Part B Proposed Rule – May 2016 May 9, 201643 State Associations Urge CMS to Withdraw Medicare Part B Proposed Rule – May 2016 May 9, 2016Rep. Scott Peters Letter to CMS Requesting Withdrawal of CMS Part B Rule – May 2016 May 2, 2016Bipartisan Congressional Letter Urging Withdrawal of CMS Part B Proposed Rule – April 2016 April 21, 2016CLSA Backgrounder on the Ensure Patient Access to Critical Breakthrough Products Act (H.R. 5009) – April 2016 April 20, 2016CLSA Endorsement Letter – HR 5009 – The Ensuring Access to Critical Breakthrough Products Act – April 2016 April 14, 2016California Patient & Provider Group Letter Opposing CMS Part B Rule – April 2016 March 17, 2016CLSA Endorsement Letter – HR 4714 – The Removing Barrier to Clinical Research Act – March 2016 March 17, 2016316 Health Care and Patient Advocacy Groups Ask Congress to Oppose CMS Part B Drug Experiment – March 2016 March 2, 2016HHS Response to Rep. Doggett Declining to Issue Guidance on the Use of March-In Rights – March 2016 January 25, 2016CLSA Response to March In Letter Rights – January 2016 May 5, 2015Letter From 500+ Stakeholder Groups in Support of IPAB Repeal — May 2015 March 4, 2015Stakeholder Letter to HHS Secretary In Support of Medicare Part D — March 2015 October 2, 2014Bipartisan Congressional Letter Urging Medicare Coverage Of FDA-Approved Obesity Medications — September 2014 August 8, 2014CHI and Stakeholder Comments to DHCS on Medi-Cal Coverage and Access Policies for Innovative Therapies (SB 870) — August 2014 March 11, 2014CHI Letter to Rep. Renee Ellmers in support of Keep the Promise to Seniors Act (H.R. 4160), Blocking CMS from Implementing Part D Proposed Rule March 4, 2014Bipartisan Letter from House Energy & Commerce, Ways & Means Committee Members Opposing CMS’ Proposed Changes to Six Protected Classes — March 4, 2014 February 18, 2014Stakeholder Letter Addressing Concerns Over CMS Medicare Advantage and Part D Proposed Rule — February 18, 2014 February 13, 2014House Republican Leadership Letter to President Obama Opposing Changes to Medicare Advantage and Part D Prescription Drug Program — February 13, 2014 February 5, 2014Senate Finance Committee Bipartisan Letter Opposing Elimination of Six Protected Classes of Prescription Drugs from Medicare Part D — February 5, 2014 November 18, 2013House Democratic Letter Urging Protection of Rare Disease Patient Interests Under Affordable Care Act — November 2013 October 7, 2013Bipartisan California Delegation Letter to CMS Protecting Diabetic Patient Access to Advanced Wound Healing Therapies — October 7, 2013 September 26, 2013Congressional Letter to President Obama Supporting Medicare Part D and Opposing Proposed Rebates — September 26, 2013 September 4, 2013HHS Office of Inspector General (OIG) Report Examines Pros, Cons Of Mandatory Manufacturer Part B Drug Rebates — September 2013 August 2, 2013Congressional Letter to Leadership Opposing Medicare Part D Rebates — August 2, 2013 June 27, 2013Bipartisan House Letter Opposing Medicare Part B Payment Cuts — June 27, 2013 May 9, 2013CHI Statement in Opposition to H.R. 1588 S. 740, to Require Manufacturers to Provide New Part D Drug Rebates — May 9, 2013 April 25, 2013CHI Letter — Support of HR351, to Repeal the Independent Payment Advisory Board (IPAB) — April 25, 2013 April 14, 2013CHI Summary of Highlights: President Barack Obama’s Fiscal Year 2014 Budget Request — April 14, 2013 March 4, 2013CHI Letter Addressing Opposition to Cuts in Medicare Part B Program — March 4, 2013
